Karyopharm Therapeutics (NASDAQ:KPTI) Shares Up 5.5%

Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) shot up 5.5% during trading on Friday . The company traded as high as $8.07 and last traded at $8.03, 2,589,127 shares were traded during trading. An increase of 41% from the average session volume of 1,841,581 shares. The stock had previously closed at $7.61.

A number of brokerages have commented on KPTI. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Monday. ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub raised shares of Zumiez from a “sell” rating to a “hold” rating in a research note on Saturday, June 22nd. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $25.00 target price (up from $15.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $17.41.

The company’s 50 day moving average is $6.37. The company has a market capitalization of $454.02 million, a price-to-earnings ratio of -2.56 and a beta of 2.43. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.25). The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.75 million. Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. Equities research analysts forecast that Karyopharm Therapeutics Inc will post -3.68 EPS for the current year.

Several hedge funds have recently made changes to their positions in the stock. Ridgeback Capital Investments L.P. acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at approximately $36,967,000. FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 51.5% in the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after purchasing an additional 637,357 shares in the last quarter. Candriam Luxembourg S.C.A. grew its holdings in shares of Karyopharm Therapeutics by 4.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 1,866,778 shares of the company’s stock valued at $10,902,000 after purchasing an additional 74,234 shares in the last quarter. Emerald Advisers LLC grew its holdings in shares of Karyopharm Therapeutics by 3.5% in the first quarter. Emerald Advisers LLC now owns 1,508,094 shares of the company’s stock valued at $8,807,000 after purchasing an additional 51,621 shares in the last quarter. Finally, Frontier Capital Management Co. LLC grew its holdings in shares of Karyopharm Therapeutics by 311.9% in the first quarter. Frontier Capital Management Co. LLC now owns 683,363 shares of the company’s stock valued at $3,991,000 after purchasing an additional 517,464 shares in the last quarter. Hedge funds and other institutional investors own 84.20% of the company’s stock.

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Featured Story: How to trade on quiet period expirations

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.